Organovo Holdings, Inc. - Common Stock (ONVO)
Frequently Asked Questions About Organovo Holdings, Inc. - Common Stock (ONVO)
Has Organovo received any funding?
Yes, Organovo has raised significant funding since its inception, including investments from institutional and private investors. This funding has assisted in the development of its 3D bioprinting technology and the expansion of the company's research capabilities.
How does Organovo ensure the quality of its bioprinted tissues?
Organovo ensures the quality of its bioprinted tissues by adhering to rigorous protocols and standards throughout the bioprinting process. This includes thorough testing for functionality, viability, and reproducibility, as well as compliance with relevant regulations and industry standards for biotech products.
How does Organovo's technology benefit drug development?
Organovo's 3D bioprinted tissues provide a more accurate platform for drug development compared to traditional 2D cell culture models. By using human tissues, the company enables researchers to better assess the efficacy and safety of new drugs, reducing reliance on animal testing and improving predictability in human responses.
Is Organovo publicly traded?
Yes, Organovo Holdings, Inc. is publicly traded on the Nasdaq exchange under the ticker symbol ONVO. The company went public through an initial public offering (IPO) in 2013, allowing it to access capital markets for growth and development.
What are clinical applications of Organovo's products?
The clinical applications of Organovo's products include using bioprinted tissues for drug testing to assess toxicity, investigating disease mechanisms, and potentially developing personalized therapies. The company's advances in bioprinting aim to address current limitations in organ transplantation and regenerative medicine.
What are some collaborations or partnerships of Organovo?
Organovo has collaborated with various academic institutions, research centers, and pharmaceutical companies to enhance its technology and broaden the applications of its products. These partnerships help facilitate the translation of its 3D bioprinting technologies to real-world medical and research settings.
What are the key markets for Organovo's products?
Organovo primarily targets the pharmaceutical and biotechnology industries as its key markets. The company’s bioprinted tissues are used for drug discovery and development, toxicology research, and personalized medicine, making them valuable for companies involved in drug research and testing.
What challenges does Organovo face in the biotechnology industry?
Like many companies in the biotechnology sector, Organovo faces challenges such as regulatory hurdles, high costs of research and development, and the need to demonstrate the clinical relevance and efficacy of its products. Additionally, competition in the rapidly evolving field of tissue engineering presents ongoing challenges.
What does Organovo Holdings, Inc. do?
Organovo Holdings, Inc. is a biotechnology company that focuses on 3D bioprinting technology to create functional human tissues for use in medical research and treatment. The company aims to revolutionize the field of regenerative medicine by providing innovative solutions for drug development, personalized medicine, and organ transplantation.
What future technologies is Organovo exploring?
Organovo is actively exploring advancements in bioprinting technologies, including the development of complex multi-tissue systems and organoids that mimic entire organ systems. The aim is to create more comprehensive models for drug testing and potentially lead to the development of bioprinted organs for transplantation.
What is 3D bioprinting?
3D bioprinting is an advanced additive manufacturing technique that uses specialized printers to layer living cells and biomaterials to create three-dimensional structures, which can mimic the function of real human tissues. This technology holds promise for various applications in medical research, drug testing, and potentially organ transplantation.
What is Organovo's vision for the future?
Organovo envisions a future where tissue engineering transforms medicine by providing on-demand, functional human tissues for transplantation and disease modeling. The company aims to lead innovations in regenerative medicine, ultimately improving patient outcomes and enabling personalized healthcare solutions.
What is the current status of Organovo's commercial products?
Organovo has introduced several products, including its 3D bioprinted liver tissues, marketed as ExVive Liver, which are used for drug testing by pharmaceutical companies. The company is focused on expanding its portfolio of tissue types and applications in the medical field.
What is the significance of Organovo's liver tissue model?
Organovo's liver tissue model, ExVive Liver, is significant because it provides a nearly human-like environment for studying liver function, drug metabolism, and toxicity. This model serves as a powerful tool for pharmaceutical research, enabling better predictions of how drugs will behave in human patients compared to traditional models.
What is the significance of Organovo's patented technology?
The patented technology of Organovo is significant because it underpins its innovative approach to bioprinting human tissues. These patents protect the proprietary methods and systems used to create functional tissues, which can enhance the company's competitive edge in the biotechnology industry.
What types of tissues does Organovo create?
Organovo specializes in creating functional human tissues that are primarily used for medical research and therapeutic applications. The company has developed printed liver tissues, kidney tissues, and other organ models that can be utilized for drug testing and toxicity assessments.
When was Organovo Holdings, Inc. founded?
Organovo Holdings, Inc. was founded in 2012, emerging from research conducted at the University of California, San Diego. The company aims to advance the science of tissue engineering and has made significant strides in developing bioprinted tissues for various applications.
Where can I find more information about Organovo?
More information about Organovo can be found on the company's official website, where you can access investor resources, press releases, and updates on their research and product developments. Additionally, financial information is available through standard investor relations platforms and the Nasdaq website.
Who are the key executives at Organovo?
Key executives at Organovo include experienced professionals from the biotechnology, pharmaceutical, and medical fields. Their leadership helps guide the company's strategy and innovation, driving the development of new bioprinted tissues and expanding Organovo's reach in the healthcare industry.
What is the current price of Organovo Holdings, Inc. - Common Stock?
The current price of Organovo Holdings, Inc. - Common Stock is 2.120
When was Organovo Holdings, Inc. - Common Stock last traded?
The last trade of Organovo Holdings, Inc. - Common Stock was at 1:48 pm EDT on April 3rd, 2025
What is the market capitalization of Organovo Holdings, Inc. - Common Stock?
The market capitalization of Organovo Holdings, Inc. - Common Stock is 18.48M
How many shares of Organovo Holdings, Inc. - Common Stock are outstanding?
Organovo Holdings, Inc. - Common Stock has 8.72M shares outstanding.